Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy-Reference-Cited by-同舟云学术

Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy

Published:2019-05-20 Issue:4 Volume:70 Page:1246-1261
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Lozano Elisa¹²,Macias Rocio I.R.¹²^ORCID,Monte Maria J.¹²,Asensio Maitane¹,Carmen Sofia³,Sanchez‐Vicente Laura¹,Alonso‐Peña Marta¹,Al‐Abdulla Ruba¹,Munoz‐Garrido Patricia⁴,Satriano Letizia⁴,O'Rourke Colm J.⁴,Banales Jesus M.⁵²,Avila Matias A.⁶²,Martinez‐Chantar Maria L.⁷²,Andersen Jesper B.⁴^ORCID,Briz Oscar¹²,Marin Jose J.G.¹²^ORCID

Affiliation:

1. Experimental Hepatology and Drug Targeting (HEVEFARM), IBSAL University of Salamanca Salamanca Spain

2. National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Health Institute Madrid Spain

3. Salamanca University Hospital, IBSAL University of Salamanca Salamanca Spain

4. Biotech Research and Innovation Centre, Department of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

5. Department of Hepatology and Gastroenterology Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU) Ikerbasque, San Sebastian Spain

6. Hepatology Programme, Center for Applied Medical Research (CIMA), IDISNA University of Navarra Pamplona Spain

7. Liver Disease Laboratory CIC bioGUNE, Technology Park of Vizcaya Vizcaya Spain

Funder

Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza

Kræftens Bekæmpelse

Secretaría de Estado de Investigación, Desarrollo e Innovación

Fundación Científica Asociación Española Contra el Cáncer

Fundación Mutua Madrileña

Instituto de Salud Carlos III

Consejería de Educación, Junta de Castilla y León

Publisher

Wiley